1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Dynamic Medical Technologies Inc.

Dynamic Medical Technologies Inc.

4138.TWO
Dynamic Medical Technologies Inc.TW flagTaipei Exchange
50.90
TWD
-0.30
- -
2.03BMarket Cap
Dynamic Medical Technologies Inc.
4138.TWO
(Taipei Exchange)

Recent

price

50.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
36.81
36.21
33.02
25.47
37.56
36.38
33.47
31.86
32.09
32.46
27.8
28.32
35.58
43.9
39.39
- -
34.67
Revenue per Share
4.65
4.75
3.48
1.17
3.32
3.34
3.26
3.12
2.89
3.1
3.2
3.39
3.78
5.79
5.14
- -
3.8
Basic EPS, GAAP
2.29
-2.44
5.43
4.36
12.14
5.57
6.37
3.32
3.61
6.48
6.61
6.48
4.47
7.97
3.17
- -
6.57
Free Cash Flow per Basic Share
1.62
4.12
4.06
3.19
1.24
2.91
3
2.94
2.81
2.6
2.77
2.89
3.06
2.6
5.58
- -
- -
Dividend per Share
17.61
14.64
13.72
10.38
13.46
13.05
12.86
12.64
12.42
12.63
12.75
12.94
13.33
18.15
15.37
- -
15.68
Book Value per Share
34.22
29.74
32.39
31.07
37.77
39.38
39.04
38.81
39.46
40.36
40.21
40.46
42.71
46.82
43.96
- -
47.22
Tangible Book Value per Share
27
33
33
35
32
36
36
36
36
36
36
36
36
36
40
- -
40
Basic Weighted Avg Shares
999
1,181
1,077
898
1,204
1,314
1,215
1,157
1,165
1,178
1,009
1,028
1,292
1,594
1,573
1,387
1,387
Sales/Revenue/Turnover
16.2
16.59
12.73
4.81
10.63
11.95
16.03
16.78
11.92
13.67
14.31
15.73
12.04
16.67
15.64
13.38
13.38
Operating Margin (%)
53
46
45
50
53
44
34
37
36
65
80
96
115
149
178
150
150
Depreciation Expense
126
155
114
41
106
121
118
113
105
113
116
123
137
210
205
152
152
Net Income, GAAP
20.56
17.5
18.75
25.94
20.63
17.81
18.79
18.39
14.14
21.19
21.55
18.49
21.5
20.03
17.82
17.47
17.47
Effective Tax Rate (%)
12.62
13.12
10.55
4.61
8.84
9.19
9.75
9.78
9.01
9.55
11.49
11.98
10.61
13.2
13.06
10.97
10.97
Profit Margin (%)
756
1,020
1,091
682
672
1,208
1,240
939
1,018
945
982
985
860
1,013
1,037
1,009
1,009
Working Capital
- -
300
308
- -
- -
290
295
- -
- -
131
118
166
231
274
347
317
317
LT Debt
929
970
1,057
1,097
1,212
1,423
1,418
1,409
1,433
1,468
1,463
1,472
1,554
1,704
1,760
1,892
1,892
Total Equity
17.82
13.9
8.11
2.29
7.65
8.69
9.12
9.15
7.5
8.13
6.85
7.91
6.83
10.4
9.17
6.78
6.78
Return on Invested Capital (%)
28.07
23.22
14.44
6.11
15.64
16.1
10.3
9.48
11.42
13.95
14.41
12.72
15.03
16.77
14
10.18
10.18
Return on Capital (%)
30.18
32.43
24.57
10.19
26.7
26.76
25.25
24.43
23.08
24.74
25.17
26.42
28.76
36.81
32.28
24.51
24.51
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
77
98
90
LT Borrowings
- -
- -
- -
LT Finance Leases
324
326
317
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
40
40
Market Capitalization
2,694
2,800
2,408

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
1,771
1,759
1,879
Cash, Cash Equivalents & STI
1,127
1,091
1,302
Accounts Receivable, Net
293
322
212
Inventories
223
222
279
Total Current Liabilities
826
792
870
Payables & Accruals
- -
- -
- -
ST Debt
77
98
90
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.95%
5.33%
7.55%
Free Cash Flow
15.41%
19.34%
107.63%
Net Income, GAAP
3.92%
8.52%
-25.97%
Sales/Revenue/Turnover
1.29%
7.55%
-11.82%
Total Cash Common Dividend
9.5%
19.73%
-32.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
393
413
378
409
1,594
2024
403
398
356
415
1,573
2025
351
327
338
370
1,387

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1.38
1.4
1.21
- -
5.79
2024
1.21
1.25
1.2
- -
5.14
2025
1.04
0.94
0.91
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.6
2024
- -
- -
- -
- -
5.58
2025
- -
- -
- -
- -
- -
Similar Companies
Clarity Pharmaceuticals Ltd (CU6.AX)
Medtronic Plc (2M6.DE)
C-Rad AB (publ) (CRAD-B.ST)
Aidite Qinhuangdao Technology Co Ltd (301580.SZ)
Lancer Orthodontics, Inc. (LANZ)
Novateor Research Laboratories (NOVATEOR.BO)
Business
Dynamic Medical Technologies Inc. (4138.TWO) develops, manufactures, and markets medical devices focused on wound care and regenerative medicine. The company offers a portfolio of advanced biological products and systems, including VIAFLO cryopreserved human placental membrane allografts for wound closure; VIAFLO dermal allografts for soft tissue repair; and cryopreserved amniotic membrane products such as DynaMatrix and DynaGraft for surgical applications; as well as extracellular matrix (ECM) scaffolds like DynaMatrix extracellular membrane and DynaGraft dermal regeneration matrix. These products target chronic wounds, burns, surgical sites, and orthopedic applications, serving healthcare providers including hospitals, clinics, and ambulatory surgery centers primarily in Taiwan and select international markets. Founded in 2018 and headquartered in New Taipei City, Taiwan, the company operates within the medical technology sector, emphasizing regenerative tissue technologies derived from human placental and amniotic tissues sourced through proprietary processing methods. Dynamic Medical Technologies maintains a focused geographic footprint in Asia, with distribution partnerships extending to North America and Europe for global reach. In recent developments, the company expanded its product pipeline with the launch of new VIAFLO-series allografts in 2024, enhancing its offerings for diabetic foot ulcers and pressure injuries. It secured a strategic distribution alliance with a major U.S. wound care distributor in early 2025, boosting North American market penetration, and completed a secondary listing preparation on the Taiwan Stock Exchange, attracting institutional investment. Additionally, Dynamic Medical Technologies announced an acquisition of a complementary biotech firm specializing in ECM technologies in late 2024, strengthening its R&D capabilities and production capacity.